undamentalytics Newsletter
Sign in

Agios Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Agios Pharmaceuticals, Inc.'s operations generated −$373m of cash; it spent $4.3m on capital projects, leaving free cash flow of −$377m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−15−50−56−59−7739−285−304−371−291−407−309−296−390−373−361
Depreciation and amortisation111136678998765—
Stock-based pay01312324248735862544945435358
Capital spending21122010571214651245
Free cash flow−17−51−58−62−9729−290−311−383−305−413−314−297−392−377−365
Free cash flow after stock pay−17−52−61−73−129−13−338−385−441−366−467−364−342−434−430−423
Share buybacks————————0080200———
Shares issued——113334016227051627700—————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AGIO vs SEPNAGIO vs KYMRAGIO vs XNCRAGIO vs FDMT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Agios Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Agios Pharmaceuticals, Inc.